A carregar...
Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma
INTRODUCTION: Prostate cancer is the second most common cancer in men worldwide. When the disease becomes resistant to androgen-deprivation therapy, treatment options are sparse. To address the high medical need in castration-resistant prostate cancer (CRPC), we generated a novel PSMAxCD3 bispecific...
Na minha lista:
| Publicado no: | BMJ Open |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Publishing Group
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7569941/ https://ncbi.nlm.nih.gov/pubmed/33067297 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2020-039639 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|